{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T21:19:46Z","timestamp":1786310386539,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Feilman Foundation Fellowship"},{"DOI":"10.13039\/501100001063","name":"Raine Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001063","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Forrest Prospect Fellowship"},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1154524"],"award-info":[{"award-number":["APP1154524"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Data"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Time-critical transcriptional events in the immune microenvironment are important for response to immune checkpoint blockade (ICB), yet these events are difficult to characterise and remain incompletely understood. Here, we present whole tumor RNA sequencing data in the context of treatment with ICB in murine models of AB1 mesothelioma and Renca renal cell cancer. We sequenced 144 bulk RNAseq samples from these two cancer types across 4 time points prior and after treatment with ICB. We also performed single-cell sequencing on 12 samples of AB1 and Renca tumors an hour before ICB administration. Our samples were equally distributed between responders and non-responders to treatment. Additionally, we sequenced AB1-HA mesothelioma tumors treated with two sample dissociation protocols to assess the impact of these protocols on the quality transcriptional information in our samples. These datasets provide time-course information to transcriptionally characterize the ICB response and provide detailed information at the single-cell level of the early tumor microenvironment prior to ICB therapy.<\/jats:p>","DOI":"10.1038\/s41597-024-03294-0","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T14:02:23Z","timestamp":1714744943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-3601","authenticated-orcid":false,"given":"Wee Loong","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-6163","authenticated-orcid":false,"given":"Rachael M.","family":"Zemek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Tilsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair R. R.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa S.","family":"Fear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda B.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joost","family":"Lesterhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-2691","authenticated-orcid":false,"given":"Timo","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"3294_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24, 541\u2013550, https:\/\/doi.org\/10.1038\/s41591-018-0014-x (2018).","journal-title":"Nat Med"},{"key":"3294_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1039\/C9ME00029A","volume":"4","author":"WL Chin","year":"2019","unstructured":"Chin, W. L., Zemek, R. M., Lesterhuis, W. J. & Lassmann, T. Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. Molecular Systems Design & Engineering 4, 689\u2013700 (2019).","journal-title":"Molecular Systems Design & Engineering"},{"key":"3294_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nrd.2016.233","volume":"16","author":"WJ Lesterhuis","year":"2017","unstructured":"Lesterhuis, W. J. et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov 16, 264\u2013272, https:\/\/doi.org\/10.1038\/nrd.2016.233 (2017).","journal-title":"Nat Rev Drug Discov"},{"key":"3294_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0299-3","author":"RM Zemek","year":"2020","unstructured":"Zemek, R. M. et al. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nat Protoc https:\/\/doi.org\/10.1038\/s41596-020-0299-3 (2020)."},{"key":"3294_CR5","doi-asserted-by":"publisher","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci Transl Med 11, https:\/\/doi.org\/10.1126\/scitranslmed.aav7816 (2019).","DOI":"10.1126\/scitranslmed.aav7816"},{"key":"3294_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32567-8","volume":"13","author":"RM Zemek","year":"2022","unstructured":"Zemek, R. M. et al. Temporally restricted activation of IFN\u00ce\u00b2 signaling underlies response to immune checkpoint therapy in mice. Nature Communications 13, 4895, https:\/\/doi.org\/10.1038\/s41467-022-32567-8 (2022).","journal-title":"Nature Communications"},{"key":"3294_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57218-9","volume":"10","author":"S Hwang","year":"2020","unstructured":"Hwang, S. et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports 10, 643, https:\/\/doi.org\/10.1038\/s41598-019-57218-9 (2020).","journal-title":"Scientific Reports"},{"key":"3294_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171, 934\u2013949.e16, https:\/\/doi.org\/10.1016\/j.cell.2017.09.028 (2017).","journal-title":"Cell"},{"key":"3294_CR9","first-page":"3358","volume":"46","author":"RR Salup","year":"1986","unstructured":"Salup, R. R. & Wiltrout, R. H. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Research 46, 3358\u20133363 (1986).","journal-title":"Cancer Research"},{"key":"3294_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications 10, 1523, https:\/\/doi.org\/10.1038\/s41467-019-09234-6 (2019).","journal-title":"Nature Communications"},{"key":"3294_CR11","author":"RM Zemek","year":"2020","unstructured":"Zemek, R. M. & Lesterhuis, W. J. GEO https:\/\/identifiers.org\/geo\/GSE153943 (2020)."},{"key":"3294_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 20, 163\u2013172, https:\/\/doi.org\/10.1038\/s41590-018-0276-y (2019).","journal-title":"Nat Immunol"},{"key":"3294_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1101\/gr.240093.118","volume":"29","author":"BA Benayoun","year":"2019","unstructured":"Benayoun, B. A. et al. Remodeling of epigenome and transcriptome landscapes with aging in mice reveals widespread induction of inflammatory responses. Genome Research 29, 697\u2013709, https:\/\/doi.org\/10.1101\/gr.240093.118 (2019).","journal-title":"Genome Research"},{"key":"3294_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12688\/f1000research.29032.2","volume":"10","author":"F M\u00f6lder","year":"2021","unstructured":"M\u00f6lder, F. et al. Sustainable data analysis with Snakemake. F1000Research 10, 33, https:\/\/doi.org\/10.12688\/f1000research.29032.2 (2021).","journal-title":"F1000Research"}],"container-title":["Scientific Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03294-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03294-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03294-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T14:04:42Z","timestamp":1714745082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41597-024-03294-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3294"],"URL":"https:\/\/doi.org\/10.1038\/s41597-024-03294-0","relation":{"references":[{"id-type":"doi","id":"10.1038\/s41596-020-0299-3","asserted-by":"subject"},{"id-type":"uri","id":"https:\/\/identifiers.org\/geo\/GSE153943","asserted-by":"subject"}]},"ISSN":["2052-4463"],"issn-type":[{"value":"2052-4463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.J.L.: consultancy Douglas Pharmaceuticals, MSD, research funding Douglas Pharmaceuticals, AstraZeneca. A.K.N. advisory boards Boehringer Ingelheim, Bayer, Roche, BMS; research funding from AstraZeneca. M.M.: Advisory boards MSD, BMS, Roche, AstraZeneca. A.B.: Founder and equity holder of the startup company INSiGENe Pty Ltd that is related to this work. A.B. is a co-founder, equity holder and directory of the startup company Respiradigm Pty Ltd that is unrelated to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}